Drug Profile
Research programme: anti-ICOS antibody - Millennium Pharmaceuticals
Alternative Names: Anti-ICOS antibody research programme - Millennium PharmaceuticalsLatest Information Update: 30 Jun 2006
Price :
$50
*
At a glance
- Originator Millennium Pharmaceuticals
- Class
- Mechanism of Action T lymphocyte inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Lung transplant rejection
Most Recent Events
- 31 Dec 2005 No development reported - Preclinical for Lung transplant rejection in USA (unspecified route)
- 21 Jun 2004 Preclinical trials in Lung transplant rejection in USA (unspecified route)